journal article·2017-10

G‐CSF loaded nanofiber/nanoparticle composite coated with collagen promotes wound healing in vivo

Shima Tanha, Morteza Rafiee‐Tehrani, Mohamad Abdollahi, Saeid Vakilian, Zahra Esmaili, Zahra Safaei Naraghi, Ehsan Seyedjafari, Hamid Akbari Javar

Publisher page

Abstract

Abstract Sustained release of functional growth factors can be considered as a beneficial methodology for wound healing. In this study, recombinant human granulocyte colony‐stimulating factor (G‐CSF)‐loaded chitosan nanoparticles were incorporated in Poly(ε‐caprolactone) (PCL) nanofibers, followed by surface coating with collagen type I. Physical and mechanical properties of the PCL nanofibers containing G‐CSF loaded chitosan nanoparticles PCL/NP(G‐CSF) and in vivo performance for wound healing were investigated. G‐CSF structural stability was evaluated through SDS_PAGE, reversed phase (RP) HPLC and size‐exclusion chromatography, as well as circular dichroism. Nanofiber/nanoparticle composite scaffold was demonstrated to have appropriate mechanical properties as a wound dresser and a sustained release of functional G‐CSF. The PCL/NP(G‐CSF) scaffold showed a suitable proliferation and well‐adherent morphology of stem cells. In vivo study and histopathological evaluation outcome revealed that skin regeneration was dramatically accelerated under PCL/NP(G‐CSF) as compared with control groups. Superior fibroblast maturation, enhanced collagen deposition and minimum inflammatory cells were also the beneficial properties of PCL/NP(G‐CSF) over the commercial dressing. The synergistic effect of extracellular matrix‐mimicking nanofibrous membrane and G‐CSF could develop a suitable supportive substrate in order to extensive utilization for the healing of skin wounds. © 2017 Wiley Periodicals Inc. J Biomed Mater Res Part A: 105A: 2830–2842, 2017.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Wound Healing and Treatments · Silk-based biomaterials and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics Faculty of Pharmacy, Tehran University of Medical Sciences Tehran Iran

Toxicology and Diseases Group Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences Tehran Iran

Department of Nanotechnology and Tissue Engineering Stem Cell Technology Research Center Tehran Iran

Departments of Dermatology and Pathology Tehran University of Medical Sciences, Razi Hospital Tehran Iran

Department of Biotechnology College of Science, University of Tehran Tehran Iran

References (33)

Show source-provided references
1. 10.1016/S0194-5998(99)70062-810.1016/S0194-5998(99)70062-8 ↗
2. EwallR;Hercules Incorporated assignee. Multi‐purpose wound dressing. U.S. Patent5 607 388.1997.
3. 10.1016/j.ijbiomac.2015.01.05110.1016/j.ijbiomac.2015.01.051 ↗
4. 10.1002/jbm.a.3568610.1002/jbm.a.35686 ↗
5. 10.1002/btpr.227010.1002/btpr.2270 ↗
6. 10.1016/j.biomaterials.2005.05.04910.1016/j.biomaterials.2005.05.049 ↗
7. 10.1016/j.biomaterials.2005.08.00410.1016/j.biomaterials.2005.08.004 ↗
8. 10.1016/j.polymdegradstab.2010.06.00710.1016/j.polymdegradstab.2010.06.007 ↗
9. 10.1016/j.burns.2010.08.01610.1016/j.burns.2010.08.016 ↗
10. Granulocyte‐macrophage colony‐stimulating factor and granulocyte colony‐stimulating factor: differential action on incisional wound healing
11. 10.1038/pj.2011.1110.1038/pj.2011.11 ↗
12. 10.1111/j.1524-475X.2006.00188.x10.1111/j.1524-475X.2006.00188.x ↗
13. Evaluation of emulsion electrospun polycaprolactone/hyaluronan/epidermal growth factor nanofibrous scaffolds for wound healing
14. 10.1016/j.biomaterials.2003.08.00710.1016/j.biomaterials.2003.08.007 ↗
15. 10.1016/j.actbio.2008.12.01310.1016/j.actbio.2008.12.013 ↗
16. 10.3727/096368909X48178210.3727/096368909X481782 ↗
17. 10.1016/j.biomaterials.2007.10.01210.1016/j.biomaterials.2007.10.012 ↗
18. 10.1002/jbm.a.3084310.1002/jbm.a.30843 ↗
19. 10.1016/S0142-9612(00)00120-410.1016/S0142-9612(00)00120-4 ↗
20. 10.1038/nbt1101-102910.1038/nbt1101-1029 ↗
21. 10.1016/S0168-3659(99)00138-810.1016/S0168-3659(99)00138-8 ↗
22. 10.1088/1468-6996/11/1/01410810.1088/1468-6996/11/1/014108 ↗
23. 10.1098/rsif.2015.025410.1098/rsif.2015.0254 ↗
24. 10.1007/s13346-013-0148-910.1007/s13346-013-0148-9 ↗
25. 10.1016/j.msec.2015.09.00710.1016/j.msec.2015.09.007 ↗
26. 10.1016/j.jconrel.2015.08.04910.1016/j.jconrel.2015.08.049 ↗
27. Medicines EDftQo. European pharmacopoeia. Strasbourg France: European Directorate for the Quality of Medicines Council of Europe Strasbourg France;2008.
28. HermanAC BooneTC LuHS.Characterization formulation and stability of Neupogen®(Filgrastim) a recombinant human granulocyte‐colony stimulating factor. Formulation characterization and stability of protein drugs: case histories: Springer;2002. p303–328.10.1007/0-306-47452-2_7 ↗
29. 10.1110/ps.023010310.1110/ps.0230103 ↗
30. 10.1016/j.actbio.2007.01.00210.1016/j.actbio.2007.01.002 ↗
31. 10.1089/ten.tea.2009.082910.1089/ten.tea.2009.0829 ↗
32. 10.1016/j.ijpharm.2014.07.02110.1016/j.ijpharm.2014.07.021 ↗
33. 10.1586/eri.11.5910.1586/eri.11.59 ↗